Xin Lang Cai Jing·2025-11-17 01:57Core Viewpoint - Junshi Bioscience's stock price has experienced fluctuations, with a year-to-date increase of 39.85% but a recent decline in the last few trading days, indicating potential volatility in the market [2]. Company Overview - Junshi Bioscience, established on December 27, 2012, and listed on July 15, 2020, is located in Shanghai and focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2]. - The company's main revenue sources are from drug sales (90.67%), technology licensing and royalties (8.74%), and technical services and others (0.59%) [2]. Financial Performance - For the period from January to September 2025, Junshi Bioscience reported a revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was -596 million yuan, showing a year-on-year increase of 35.72% in losses [2]. Stock Performance - As of November 17, Junshi Bioscience's stock price was 38.22 yuan per share, with a market capitalization of 39.24 billion yuan. The stock has seen a recent decline of 2.03% [1]. - The stock has experienced a slight decrease of 0.44% over the last five trading days, a 1.16% decline over the last 20 days, and a 9.00% drop over the last 60 days [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Junshi Bioscience was 35,900, an increase of 15.17% from the previous period. The average circulating shares per person decreased by 12.96% to 21,361 shares [2]. - The top ten circulating shareholders include notable ETFs, with E Fund's SSE STAR 50 ETF holding 19.39 million shares, a decrease of 2.82 million shares from the previous period [3].